The Director Global Market Access & Pricing role for frexalimab contributes to pricing and market access strategy and supports its end-to-end execution for relapsing multiple sclerosis (RMS) and non-relapsing secondary progressive multiple sclerosis (nrSPMS). Frexalimab is a potential first-in-class anti-CD40L antibody with Phase 3 studies underway in these indications. Strategic decisions made for MS may also influence potential follow-on indications across immunology and metabolic diseases. The role is part of Sanofi’s Global Market Access & Pricing Neurology Team within the Specialty Care Global Market Access organization. It works closely with Commercial, Medical, Clinical, Evidence for Access, Global Pricing, Biostatistics, Regulatory Affairs, Public Affairs, and country teams. The position develops access and pricing strategies intended to support timely patient access and value recognition by payers, while helping shape the MS market environment and prepare for launch.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director